Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Jeffrey Stein, insider at Cidara Therapeutics
Jeffrey Stein Insider Alerts

Get notified the next time Jeffrey Stein buys or sells Cidara Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Jeffrey Stein Insider Information

Dr. Stein has been President, CEO and Director of Cidara since January 2014. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014. Tedizolid is now marketed by Merck under the name Sivextro. Dr. Stein currently serves as a Director of Paratek Pharmaceuticals (NASDAQ: PRTK) and Ideaya Biosciences. He is also founding Chairman and President of the Antimicrobials Working Group, an industry leading 501(c)(6) organization. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.

What is Jeffrey Stein's net worth?

The estimated net worth of Jeffrey Stein is at least $429,126.40 as of September 24th, 2019. Dr. Stein owns 282,320 shares of Cidara Therapeutics stock worth more than $429,126 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Stein may own. Learn More.

What is Jeffrey Stein's salary?

As the CEO of Cidara Therapeutics, Inc., Dr. Stein earned a total compensation package of $1,289,432.00 in 2020. Dr. Stein earned a salary of $542,000.00, options awards of $451,902.00, non-equity compensation of $292,680.00, and other compensation of $2,850.00.

How do I contact Jeffrey Stein?

The corporate mailing address for Dr. Stein and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]

Has Jeffrey Stein been buying or selling shares of Cidara Therapeutics?

In the last ninety days, Jeffrey Stein has bought $79,500.00 in shares of Cidara Therapeutics stock. Most recently, on Friday, November 12th, Jeffrey Stein bought 50,000 shares of Cidara Therapeutics stock. The stock was acquired at an average cost of $1.59 per share, with a total value of $79,500.00.

Who are Cidara Therapeutics' active insiders?

Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Jessica Oien (General Counsel), Preetam Shah (CFO), and Jeffrey Stein (CEO).

Are insiders buying or selling shares of Cidara Therapeutics?

In the last twelve months, Cidara Therapeutics insiders bought shares 4 times. They purchased a total of 117,000 shares worth more than $193,940.00. In the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 6,931 shares worth more than $16,221.26. The most recent insider tranaction occured on November, 12th when CEO Jeffrey Stein bought 50,000 shares worth more than $79,500.00. Insiders at Cidara Therapeutics own 8.0 % of the company.

Information on this page was last updated on 11/12/2021.

Jeffrey Stein Insider Trading History at Cidara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/12/2021Buy50,000$1.59$79,500.00View SEC Filing Icon  
8/18/2021Buy40,000$1.72$68,800.00View SEC Filing Icon  
9/24/2019Buy52,500$1.91$100,275.00282,320View SEC Filing Icon  
5/23/2018Buy212,766$4.70$1,000,000.20View SEC Filing Icon  
9/12/2017Buy7,350$6.79$49,906.5051,851View SEC Filing Icon  
6/5/2017Buy15,000$5.95$89,250.00View SEC Filing Icon  
3/31/2017Buy12,900$7.75$99,975.00View SEC Filing Icon  
5/20/2016Buy4,310$11.51$49,608.1012,100View SEC Filing Icon  
11/25/2015Buy6,700$15.09$101,103.006,700View SEC Filing Icon  
See Full Table

Jeffrey Stein Buying and Selling Activity at Cidara Therapeutics

This chart shows Jeffrey Stein's buying and selling at Cidara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cidara Therapeutics Company Overview

Cidara Therapeutics logo
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $1.52
Low: $1.48
High: $1.64

50 Day Range

MA: $1.67
Low: $1.40
High: $2.35

2 Week Range

Now: $1.52
Low: $1.31
High: $3.15

Volume

1,178,144 shs

Average Volume

708,694 shs

Market Capitalization

$101.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!